Vol. 5, Issue 2, Part A (2023)

Introduction: Anti-TNF drugs have transformed IBD treatment since their introduction over two decades ago. Anti-TNF drugs like infliximab (IFX) and adalimumab (ADA) can elicit and maintain corticosteroid-free remission in adults and adolescents with Crohn's disease (CD) and ulcerative colitis. For decades, corticosteroid (CS) has been the main treatment for IBD, despite its substantial side effects, especially on growth and development.
The aim: This article demonstrated study on anti-TNF therapy in pediatric IBD (inflammatory bowel disease).
Methods: This study demonstrated that it met all of the requirements by comparing itself to the Preferred Reporting Items for Systematic Review and Meta-Analysis (PRISMA) 2020 guidelines. As a result, the specialists were able to ensure that the study was as up to date as possible. Publications published between 2013 and 2023 were considered for this search strategy. This was accomplished using a variety of online reference sources, including Pubmed and SagePub. It was chosen not to include review pieces, previously published works, or works that were just partially completed.
Result: In the PubMed database, the results of our search brought up 46 articles and SagePub 52 articles. The results of the search conducted for the last year of 2013 yielded a total 11 articles for PubMed and 9 articles from SagePub. In the end, we compiled a total of four papers.
Conclusion: Early anti-TNF treatment is becoming more common in juvenile inflammatory bowel disease, notably Crohn's. Targeting higher dosages (> 5 µg/mL) with proactive TDM has been proven to increase disease remission rates and anti-TNF biologic durability in real-world and clinical investigations in children.